Maalouf Rita, Bailey Steven
Department of Sciences, Faculty of Natural and Applied Sciences, Notre Dame University Louaize, P.O. Box 72, Zouk Mikael, Zouk Mosbeh, Lebanon.
Division of Cardiology, Department of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX, 78229-3900, USA.
Heart Fail Rev. 2016 Sep;21(5):567-78. doi: 10.1007/s10741-016-9544-9.
Since its discovery in 1988, B-type natriuretic peptide (BNP) has been recognized as a powerful cardiovascular biomarker for a number of disease states, specifically heart failure. Concurrent with such a discovery, much effort has been allocated to the precise monitoring of physiological BNP levels. Thus, it can be used to guide the therapy of heart failure and determine the patient's stage of disease. Thus, we discuss in this article BNP as a potent biomarker. Subsequently, we will review the progress of biosensing devices as they could be applied to monitor BNP levels as assays, benchtop biosensors and implantable biosensors. The analytical characteristics of commercially available BNP assays are presented. Still emerging as a field, we define four obstacles that present opportunity for the future development of implantable biosensor: foreign body response, sensor renewability, sensitivity and selectivity.
自1988年发现以来，B型利钠肽（BNP）已被公认为多种疾病状态（特别是心力衰竭）的一种强大的心血管生物标志物。伴随着这一发现，人们投入了大量精力来精确监测生理状态下的BNP水平。因此，它可用于指导心力衰竭的治疗并确定患者的疾病阶段。因此，我们在本文中讨论BNP作为一种有效的生物标志物。随后，我们将回顾生物传感设备的进展，因为它们可作为检测方法、台式生物传感器和植入式生物传感器应用于监测BNP水平。介绍了市售BNP检测方法的分析特性。作为一个仍在兴起的领域，我们定义了植入式生物传感器未来发展面临机遇的四个障碍：异物反应、传感器可更新性、灵敏度和选择性。
